PlattL, EasterbrookP, GowerE, et al.Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis. Lancet Infect Dis., 2016; 16(7):797–808; doi: 10.1016/S1473-3099(15)00485-5
2.
ChenTY, DingEL, SeageGR3rd, et al.Meta-analysis: Increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis., 2009; 49(10):1605–1615; doi: 10.1086/644771
3.
Lo ReV3rd, KallanMJ, TateJP, et al.Hepatic decompensation in antiretroviral-treated patients with HIV/hepatitis C virus coinfection compared with hepatitis C virus monoinfection. Ann Intern Med., 2014; 160(6):369–379; doi: 10.7326/M13-1829
4.
WeberR, SabinCA, Friis-MøllerN, et al.Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med, 2006; 166(15):1632–1641; doi: 10.1001/archinte.166.15.1632
5.
RequenaM-B, GrabarS, LanoyE, et al.Mortality in hepatitis C virus–cured vs. hepatitis C virus–uninfected people with HIV. AIDS., 2023; 37(8):1297–1306; doi: 10.1097/QAD.0000000000003569
6.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med., 2021; 18(3):e1003583; doi: 10.1371/journal.pmed.1003583
MillerMF, HaleyC, KozielMJ, et al.Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: A meta-analysis. Clin Infect Dis., 2005; 41(5):713–720; doi: 10.1086/432618
9.
BräuN, FoxRK, XiaoP, et al.; North American Liver Cancer in HIV Study Group. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. J Hepatol, 2007; 47(4):527–537; doi: 10.1016/j.jhep.2007.06.010
10.
ShafranSD. HIV coinfected have similar SVR rates as HCV monoinfected with DAAs: It’s time to end segregation and integrate HIV patients into HCV trials. Clin Infect Dis., 2015; 61(7):1127–1134; doi: 10.1093/cid/civ438
11.
Salmon-CeronD, NahonP, LayeseR, et al.; ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups. HIV/HCV coinfected patients with cirrhosis are no longer at higher risk for hepatocellular carcinoma or end-stage liver disease compared to HCV monoinfected patients. Hepatology, 2019; 70(3):939–954; doi: 10.1002/hep.30400
12.
Hosseini-HooshyarS, HajarizadehB, BajisS, et al.Risk of hepatitis C reinfection following successful therapy among people living with HIV: A global systematic review, meta-analysis, and meta-regression. Lancet HIV, 2022; 9(6):e414–e427; doi: 10.1016/S2352-3018(22)00077-7
